Centessa Pharma ADR saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 68 to 79.
Can You Really Time The Stock Market?
This proprietary rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the best stocks tend to have an 80 or better RS Rating as they launch their biggest price moves. See if Centessa Pharma ADR can continue to rebound and clear that threshold.
While the stock is not near an ideal buying range right now, see if it is able to form and break out of a proper base.
The company showed 0% earnings growth last quarter, while sales growth came in at -100%.
The company holds the No. 12 rank among its peers in the Medical-Research Equipment/Services industry group. Agilent Technologies, Charles River Labs Intl and Medpace Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
